AU654031B2 - Pharmaceuticals for the treatment of rejection reactions in organ transplantations - Google Patents

Pharmaceuticals for the treatment of rejection reactions in organ transplantations Download PDF

Info

Publication number
AU654031B2
AU654031B2 AU21247/92A AU2124792A AU654031B2 AU 654031 B2 AU654031 B2 AU 654031B2 AU 21247/92 A AU21247/92 A AU 21247/92A AU 2124792 A AU2124792 A AU 2124792A AU 654031 B2 AU654031 B2 AU 654031B2
Authority
AU
Australia
Prior art keywords
organ
compound
administered
recipient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU21247/92A
Other languages
English (en)
Other versions
AU2124792A (en
Inventor
Robert Ryder Bartlett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU2124792A publication Critical patent/AU2124792A/en
Application granted granted Critical
Publication of AU654031B2 publication Critical patent/AU654031B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
AU21247/92A 1991-08-22 1992-08-21 Pharmaceuticals for the treatment of rejection reactions in organ transplantations Expired AU654031B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4127737 1991-08-22
DE4127737A DE4127737A1 (de) 1991-08-22 1991-08-22 Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen

Publications (2)

Publication Number Publication Date
AU2124792A AU2124792A (en) 1993-02-25
AU654031B2 true AU654031B2 (en) 1994-10-20

Family

ID=6438804

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21247/92A Expired AU654031B2 (en) 1991-08-22 1992-08-21 Pharmaceuticals for the treatment of rejection reactions in organ transplantations

Country Status (18)

Country Link
US (3) US5728721A (enExample)
EP (1) EP0529500B1 (enExample)
JP (1) JP3285226B2 (enExample)
KR (1) KR100253450B1 (enExample)
AT (1) ATE113835T1 (enExample)
AU (1) AU654031B2 (enExample)
CA (1) CA2076555C (enExample)
CZ (1) CZ281353B6 (enExample)
DE (2) DE4127737A1 (enExample)
DK (1) DK0529500T3 (enExample)
ES (1) ES2065738T3 (enExample)
HU (1) HU219402B (enExample)
IL (1) IL102886A (enExample)
MX (1) MX9204875A (enExample)
RU (1) RU2067862C1 (enExample)
SK (1) SK279323B6 (enExample)
TW (1) TW210284B (enExample)
ZA (1) ZA926310B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
PT787491E (pt) * 1994-10-17 2000-11-30 Aventis Pharma Ltd Composicao para a profilaxia e para o tratamento de doencas alergicas de tipo i
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
DE19857009A1 (de) * 1998-12-10 2000-06-15 Aventis Pharma Gmbh Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
DE19960443C2 (de) * 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
WO2003039231A2 (en) * 2001-10-25 2003-05-15 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2005011669A1 (ja) * 2003-08-05 2005-02-10 Dainippon Sumitomo Pharma Co., Ltd. 経皮投与用医薬組成物
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
DE102005017592A1 (de) * 2005-04-16 2006-10-19 Lindner, Jürgen, Dr. med. Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436263C2 (de) 1974-07-27 1983-02-17 Hoechst Ag, 6000 Frankfurt Thiazolidinderivate und Verfahren zu ihrer Herstellung
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
GB8320969D0 (en) * 1983-08-03 1983-09-07 Ici Plc Transparent sheet
DE3405727A1 (de) 1984-02-17 1985-08-22 Hoechst Ag, 6230 Frankfurt Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
DE4101324A1 (de) 1991-01-18 1992-07-23 Hoechst Ag Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
EP0538783B1 (de) 1991-10-23 1995-09-27 Hoechst Aktiengesellschaft N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
US6223209B1 (en) * 1997-09-30 2001-04-24 Ncr Corporation Distributed world wide web servers

Also Published As

Publication number Publication date
SK258292A3 (en) 1995-09-13
SK279323B6 (sk) 1998-10-07
EP0529500A1 (de) 1993-03-03
EP0529500B1 (de) 1994-11-09
US20050080118A1 (en) 2005-04-14
HUT64845A (en) 1994-03-28
KR930003915A (ko) 1993-03-22
JPH05208909A (ja) 1993-08-20
HU219402B (hu) 2001-04-28
US6288098B1 (en) 2001-09-11
JP3285226B2 (ja) 2002-05-27
DE4127737A1 (de) 1993-02-25
TW210284B (enExample) 1993-08-01
ZA926310B (en) 1993-04-28
DE59200773D1 (de) 1994-12-15
CZ258292A3 (en) 1993-03-17
ES2065738T3 (es) 1995-02-16
US5728721A (en) 1998-03-17
CA2076555A1 (en) 1993-02-23
MX9204875A (es) 1993-02-01
US7402601B2 (en) 2008-07-22
AU2124792A (en) 1993-02-25
RU2067862C1 (ru) 1996-10-20
CA2076555C (en) 2003-07-29
KR100253450B1 (ko) 2000-07-01
DK0529500T3 (da) 1995-04-18
ATE113835T1 (de) 1994-11-15
IL102886A0 (en) 1993-01-31
CZ281353B6 (cs) 1996-09-11
IL102886A (en) 1996-01-19

Similar Documents

Publication Publication Date Title
US5728721A (en) Pharmaceuticals for the treatment of rejection reactions in organ transplantations
JP2514190B2 (ja) 全身性エリテマト−デス治療剤
IE64760B1 (en) 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
JP3119738B2 (ja) Ｎ−フェニル−２−シアノ−３−ヒドロキシクロトンアミド誘導体および免疫調整性を有する医薬品としてのその使用
US6133301A (en) Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5504084A (en) Pharmaceutical for the treatment of skin disorders
JP2706371B2 (ja) 癌治療用補助剤及びそれを用いたキット
EP1562571B1 (en) Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
US5503830A (en) Compounds having immunostimulating activity and methods of use thereof
EP0184100B1 (en) Use of spergualin or a pharmaceutically acceptable salt thereof for the preparation of a transplantation immunity suppressing and anti-allergic agent
KR0132568B1 (ko) 이뇨 또는 항고혈압 조성물
JPH06135836A (ja) コントラサプレッサー細胞の誘導剤
US20240197816A1 (en) Composition and method for prolong survival of transplant and recipient
LT3589B (en) Using of known combination for treatment of rejection reaction by transplantation of organs
DE19923961A1 (de) Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen
US4439445A (en) Cytoprotective use of oxamate derivatives
JPH08119860A (ja) 脂肪肝の予防または治療剤
Paramjit Kaur Management and treatment of heartworm infections in dogs.
HK1074797B (en) Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
WO1992004894A1 (fr) Antirhumatismal